Fierce Drug Dev Forum 2019 has ended
avatar for Meeta Chatterjee, Ph.D.

Meeta Chatterjee, Ph.D.

Senior Vice President, Global Business Development
Meeta Chatterjee is SVP, Global Business Development for Legend Biotech. Legend Biotech is focused on CAR-T and Cell Therapies for oncology and infectious diseases. Meeta currently provides oversight for all business development activities including prioritizing opportunities, managing evaluations and executing transactions. Meeta also leads Alliance Management activities at Legend.

Meeta has more than 30 years of broad strategic and operational experience in pharmaceutical research & development, in-licensing and externalization activities. Prior to joining Legend, she was Head of Strategy, Transactions and Operations in the Business Development and Licensing (BD&L) group at Merck Research Labs. In that role, Meeta oversaw all discovery and late-stage transactions worldwide and early-stage transactions in geographies not served by Merck’s BD&L Innovation Hubs. Meeta also provided oversight for Merck’s out- licensing activities which included externalization of development compounds/programs, technologies, devices, and formulations to targeted partner organizations.

Meeta started her career in the Cardiovascular Discovery Research group at Schering-Plough. As Head of the Vascular Biology group, she led research efforts in the areas of hypertension, atherosclerosis and obesity, and was a key member of the teams responsible for the discovery and development of Zetia® and Zontivity®. Meeta received her undergraduate education at St. Xavier’s University in Ahmedabad, India and Rutgers University (BA, Physics). She received a PhD in Physiology from Rutgers University and completed a postdoctoral fellowship in the Department of Physiology at The University of Virginia School of Medicine.